The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Open accessAbstract
The transmembrane protein Tim-3 has been shown to negatively regulate T-cell-dependent immune responses and was recently demonstrated to be associated with the phenomenon of immune exhaustion, which can occur as a consequence of chronic viral infection. Unlike other negative regulators of T-cell function (e.g., PD-1), Tim-3 does not contain any obvious inhibitory signaling motifs. We have found that ectopic expression of Tim-3 in T cells leads to enhancement of T-cell receptor (TCR)-dependent signaling pathways, which was observed at the level of transcriptional reporters and endogenous cytokine production. We have exploited this observation to dissect what elements within the cytoplasmic tail of Tim-3 are required for coupling to downstream signaling pathways. Here we have demonstrated that two of the more membrane-proximal cytoplasmic tail tyrosines are required for Tim-3 signaling to T-cell activation pathways in a redundant fashion. Furthermore, we show that Tim-3 can directly bind to the Src family tyrosine kinase Fyn and the p85 phosphatidylinositol 3-kinase (PI3K) adaptor. Thus, at least under conditions of short-term stimulation, Tim-3 can augment T-cell activation, although this effect can be blocked by the inclusion of an agonistic antibody to Tim-3. These findings should help further the study of Tim-3 function in other physiological settings, such as those that lead to immune exhaustion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, tyrosine kinase FYN and human leukocyte antigen B (HLA‐B)‐associated transcript 3 (BAT3) were suggested to inhibit the cytoplasmic tail of TIM‐3 signaling [307, 308, 309].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [309]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,046
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citationBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citationScansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs
Obenauer, J. C. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg584 · Cited by 1,609
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Self-citation
Research works printed but not linked: 1
- Obenauer J. C., 2004, Methods Mol. Biol, 261, 445
Cited by
Sorted by citations
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citationImmune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,418
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Self-citationTim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Self-citationNavigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 747
Birge, R. B., Boeltz, S., Kumar, S., Carlson, J., Wanderley, J. L. M., Calianese, D. C., Barcinski, M. A., Brekken, R. A., Huang, X., Hutchins, J., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.11 · Cited by 744
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Self-citationTim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Ndhlovu, L. C., López‐Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 512
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, N., Sabatos-Peyton, C. A., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 409
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394
Self-citationTIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Gleason, M., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M., Cooley, S., Verneris, M. R., Cichocki, F. M., Holman, C., Panoskaltsis‐Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 383
NK Cell-Based Immune Checkpoint Inhibition
Khan, M. B., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 367
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330
“In line with the TIL scRNA-seq result, Dhx37 mutant have higher levels of surface PD-1, Lag3 and Tim-3 (Figure 5D–F), which are known immune checkpoints and also linked to intrinsic T cell activation (Lee et al., 2011).”
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
T cell exhaustion during persistent viral infections
Kahan, S. M., Wherry, E. J., & Zajac, A. J. (2015) · Virology · doi:10.1016/j.virol.2014.12.033 · Cited by 327
Targeting cell signaling in allergic asthma
Athari, S. S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0079-0 · Cited by 324
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Joller, N., Anderson, A. C., & Kuchroo, V. K. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.010 · Cited by 296
Self-citationKikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh‐Tabrizi, S., Shima, T., Takayanagi, S., Niiro, H., Yurino, A., Miyawaki, K., Takenaka, K., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.07.011 · Cited by 288
Li, J., Jie, H.-B., Lei, Y. L., Gildener‐Leapman, N., Trivedi, S., Green, T., Kane, L., & Ferris, R. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 256
Self-citationTIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Du, W., Yang, M., Turner, A., Xu, C., Ferris, R. L., Huang, J., Kane, L., & Lu, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030645 · Cited by 242
Self-citationTIM-3, a promising target for cancer immunotherapy
He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235
TIM-3: An update on immunotherapy
Zhao, L., Cheng, S., Fan, L., Zhang, B., & Xu, S. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107933 · Cited by 224
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
Mercier, I. L., Lines, J. L., & Noelle, R. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00418 · Cited by 202
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 205
Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
Cao, Y., Wang, X., Jin, T., Tian, Y., Dai, C., Widarma, C., Song, R., & Xu, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00348-8 · Cited by 191
Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
Ferris, R. L., Lu, B., & Kane, L. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400557 · Cited by 171
Self-citationAvery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 171
Self-citationThe TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Kandel, S., Adhikary, P., Li, G., & Cheng, K. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.011 · Cited by 172
Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance
Tang, R., Rangachari, M., & Kuchroo, V. K. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101302 · Cited by 156
Self-citationJi, J., Yin, Y., Ju, H., Xu, X., Liu, W., Fu, Q., Hu, J., Zhang, X., & Sun, B. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0528-7 · Cited by 156
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Çevik, N. C., Sever, E. A., Unutmaz, D., Ceyhan, G. O., Demir, İ. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 160
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 157
Tan, S., Xu, Y., Wang, Z., Wang, T., Du, X., Song, X., Guo, X., Peng, J., Zhang, J., Liang, Y., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2332 · Cited by 147
Not All Immune Checkpoints Are Created Equal
Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 156
The three main stumbling blocks for anticancer T cells
Baitsch, L., Marraco, S. A. F., Legat, A., Meyer, C., & Speiser, D. E. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.006 · Cited by 148
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
Gupta, S., Thornley, T. B., Gao, W., Larocca, R., Turka, L. A., Kuchroo, V. K., & Strom, T. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45138 · Cited by 139
Self-citationT Cell Ig Mucin-3 Promotes Homeostasis of Sepsis by Negatively Regulating the TLR Response
Yang, X., Jiang, X., Chen, G., Xiao, Y., Geng, S., Kang, C., Zhou, T., Li, Y., Guo, X., He, X., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202661 · Cited by 139
Joller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 145
Self-citationMöller‐Hackbarth, K., Dewitz, C., Schweigert, O., Trad, A., Garbers, C., Rose‐John, S., & Scheller, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.488478 · Cited by 141
Clayton, K. L., Haaland, M. S., Douglas-Vail, M. B., Mujib, S., Chew, G. M., Ndhlovu, L. C., & Ostrowski, M. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302663 · Cited by 134
TIM-3 Regulates Distinct Functions in Macrophages
Ocaña‐Guzmán, R., Torre-Bouscoulet, L. I., & Sada‐Ovalle, I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00229 · Cited by 122
Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
Scharping, N. E., & Delgoffe, G. M. (2016) · Vaccines · doi:10.3390/vaccines4040046 · Cited by 120
Hamilton, K. S., Phong, B. L., Corey, C. G., Cheng, J., Gorentla, B. K., Zhong, X., Shiva, S., & Kane, L. (2014) · Science Signaling · doi:10.1126/scisignal.2005169 · Cited by 124
Self-citationSabatos-Peyton, C. A., Nevin, J. T., Brock, A., Venable, J. D., Tan, D. J., Kassam, N., Xu, F., Taraszka, J. A., Wesemann, L. D., Pertel, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1385690 · Cited by 118
Self-citationThe Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
Sun, H., & Sun, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02354 · Cited by 121
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation
Phong, B. L., Avery, L., Sumpter, T. L., Gorman, J. V., Watkins, S. C., Colgan, J. D., & Kane, L. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150388 · Cited by 110
Self-citationİmani, S., Farghadani, R., Roozitalab, G., Maghsoudloo, M., Emadi, M., Moradi, A., Abedi, B., & Kaboli, P. J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03394-8 · Cited by 112
Banerjee, H., Nieves-Rosado, H. M., Kulkarni, A., Murter, B., McGrath, K. V., Chandran, U. R., Chang, A., Szymczak-Workman, A. L., Vujanovic, L. N., Delgoffe, G. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109699 · Cited by 103
Self-citationHuang, S., Liu, D., Sun, J., Zhang, H., Zhang, J., Wang, Q., Gan, L., Qu, G., Qiu, J., Deng, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.12.013 · Cited by 101
Immune Checkpoint Molecules in Reproductive Immunology
Mikó, É., Meggyes, M., Doba, K., Barakonyi, A., & Szereday, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00846 · Cited by 99
The role of phosphatidylserine on the membrane in immunity and blood coagulation
Wang, J., Yu, C., Zhuang, J., Qi, W., Jiang, J., Liu, X., Zhao, W., Cao, Y., Wu, H., Qi, J., et al. (2022) · Biomarker Research · doi:10.1186/s40364-021-00346-0 · Cited by 103
Qiu, Y., Chen, J., Liao, H., Zhang, Y., Wang, H., Li, S., Luo, Y., Fang, D., Li, G., Zhou, B., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002984 · Cited by 94
Meggyes, M., Mikó, É., Polgár, B., Bogar, B., Farkas, B., Illés, Z., & Szereday, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092371 · Cited by 92
Kumar, S., Calianese, D. C., & Birge, R. B. (2017) · Immunological Reviews · doi:10.1111/imr.12587 · Cited by 93
Banerjee, H., & Kane, L. (2018) · F1000Research · doi:10.12688/f1000research.13446.1 · Cited by 91
Self-citationZhang, W., Zhang, Y., He, Y., Wang, X., & Fang, Q. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.02.007 · Cited by 93
Tim-3 Directly Enhances CD8 T Cell Responses to Acute Listeria monocytogenes Infection
Gorman, J. V., Starbeck-Miller, G. R., Pham, N., Traver, G. L., Rothman, P. B., Harty, J. T., & Colgan, J. D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302290 · Cited by 91
TIM-3 pathway dysregulation and targeting in cancer
Zeidan, A. M., Komrokji, R. S., & Brunner, A. M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1865814 · Cited by 92
Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
Zhang, H., Song, Y., Yang, H., Liu, Z., Gao, L., Liang, X., & Ma, C. (2018) · Oncogene · doi:10.1038/s41388-018-0140-4 · Cited by 85
Beyond T cell exhaustion: TIM-3 regulation of myeloid cells
Dixon, K. O., Lahore, G. F., & Kuchroo, V. K. (2024) · Science Immunology · doi:10.1126/sciimmunol.adf2223 · Cited by 87
Self-citationRegulation of T cell responses by the receptor molecule Tim-3
Gorman, J. V., & Colgan, J. D. (2014) · Immunologic Research · doi:10.1007/s12026-014-8524-1 · Cited by 83
Tomkowicz, B. E., Walsh, E. S., Cotty, A., Verona, R. I., Chi-Sabins, N., Kaplan, F. M., Santulli-Marotto, S., Chin, C., Mooney, J. M., Lingham, R. B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140694 · Cited by 87
A cellular platform for the evaluation of immune checkpoint molecules
Jutz, S., Hennig, A., Paster, W., Asrak, Ö., Dijanovic, D., Kellner, F., Pickl, W. F., Huppa, J. B., Leitner, J. M., & Steinberger, P. (2017) · Oncotarget · doi:10.18632/oncotarget.17615 · Cited by 79
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Yan, Z., Wang, C., Wu, J., Wang, J., & Ma, T. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00267-6 · Cited by 81
Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, W. J., Hobo, W. A., van der Voort, R., & Dolstra, H. (2012) · Blood · doi:10.1182/blood-2012-02-412510 · Cited by 76
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
de Morais, A. L. G., Cerdá, S. S., & Miguel, M. J. D. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01218-y · Cited by 73
Immune Checkpoint Receptors Signaling in T Cells
Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 74
Characterizing Functional Domains for TIM-Mediated Enveloped Virus Entry
Møller-Tank, S., Albritton, L. M., Rennert, P. D., & Maury, W. J. (2014) · Journal of Virology · doi:10.1128/jvi.00300-14 · Cited by 71
TIM-3 in Leukemia; Immune Response and Beyond
Rezaei, M., Tan, J., Zeng, C., Li, Y., & Ganjalıkhani-Hakemi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.753677 · Cited by 70
Shao, J., Yin, W., Zhang, Q., Liu, Q., Peng, M., Hu, H. ‐., Hu, P., Ren, H., & Zhang, D. ‐. (2016) · Scandinavian Journal of Immunology · doi:10.1111/sji.12455 · Cited by 67
Morimoto, T., Nakazawa, T., Matsuda, R., Nishimura, F., Nakamura, M., Yamada, S., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073489 · Cited by 66
Impact of Exogenous Galectin-9 on Human T Cells
Lhuillier, C., Barjon, C., Niki, T., Gelin, A., Praz, F., Moralès, O., Souquère, S., Hirashima, M., Wei, M., Dellis, O., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.661272 · Cited by 66
Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer
Riese, M. J., Moon, E. K., Johnson, B. D., & Albelda, S. Μ. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00108 · Cited by 65
Maurya, N., Gujar, R., Gupta, M., Yadav, V., Verma, S., & Sen, P. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400395 · Cited by 62
Phosphatidylserine binding directly regulates TIM-3 function
Smith, C. M., Li, A., Krishnamurthy, N., & Lemmon, M. A. (2021) · Biochemical Journal · doi:10.1042/bcj20210425 · Cited by 61
Grabmeier‐Pfistershammer, K., Stecher, C., Zettl, M., Rosskopf, S., Rieger, A., Zlabinger, G. J., & Steinberger, P. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.09.002 · Cited by 61
Zhang, W., Jordan, K. R., Schulte, B., & Purev, E. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s175113 · Cited by 60
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Poggi, A. D., & Zocchi, M. R. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.016 · Cited by 58
Mikó, É., Meggyes, M., Bogar, B., Schmitz, N., Barakonyi, A., Várnagy, Á., Farkas, B., Tamás, P., Bódis, J., Szekeres‐Barthó, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071811 · Cited by 58
PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
Edwards, S. C., Hedley, A., Hoevenaar, W. H. M., Wiesheu, R., Glauner, T. A., Kilbey, A., Shaw, R., Boufea, K., Batada, N. N., Hatano, S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211431 · Cited by 57
Li, J., Shayan, G., Avery, L., Jie, H.-B., Gildener‐Leapman, N., Schmitt, N. C., Lü, B., Kane, L., & Ferris, R. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1200778 · Cited by 58
Self-citationCancer cell intrinsic TIM-3 induces glioblastoma progression
Guo, Q., Shen, S., Guan, G., Zhu, C. Y., Zou, C., Cao, J., Cheng, W., Xu, X., Yu, J., Lin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105329 · Cited by 55
Self-citationPatsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 57
T cell exhaustion in cancer: Mechanisms and clinical implications
Wang, J., Xu, Y., Huang, Z., & Lu, X. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26645 · Cited by 56
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 55
Gandhi, A. K., Kim, W. M., Sun, Z.-Y. J., Huang, Y., Bonsor, D. A., Sundberg, E. J., Kondo, Y., Wagner, G., Kuchroo, V. K., Petsko, G. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35754-0 · Cited by 53
Self-citationKataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 52
Self-citationThe Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Ganjalıkhani-Hakemi, M., Jafarinia, M., Azizi, M., Rezaeepoor, M., Isayev, O., & Bazhin, A. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.601661 · Cited by 53
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 51
Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
Hervás‐Stubbs, S., Soldevilla, M. M., Villanueva, H., Mancheño, U., Bendandi, M., & Pastor, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6608 · Cited by 50
Rhein, B. A., Brouillette, R. B., Schaack, G. A., Chiorini, J. A., & Maury, W. J. (2016) · Journal of Virology · doi:10.1128/jvi.00100-16 · Cited by 49
Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections
Kared, H., Martelli, S., Tan, S. W., Simoni, Y., Chong, M. L., Yap, S. H., Newell, E. W., Pender, S. L. F., Kamarulzaman, A., Rajasuriar, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00686 · Cited by 54
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 48
Iwasaki, H., Yasutan, H. C., Ashino, Y., & Hattori, T. (2021) · Biomolecules · doi:10.3390/biom11030430 · Cited by 48
Sakoda, T., Kikushige, Y., Miyamoto, T., Irifune, H., Harada, T., Hatakeyama, K., Kunisaki, Y., Kato, K., & Akashi, K. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008405 · Cited by 47
Schwartz, J. A., Clayton, K., Mujib, S., Zhang, H., Rahman, A. K. M. N.-U., Liu, J., Yue, F. Y., Benko, E., Kovacs, C. M., & Ostrowski, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601298 · Cited by 47
Metadata
- Authors
- Lee, J., Su, E. W., Zhu, C., Hainline, S., Phuah, J., Moroco, J. A., Smithgall, T. E., Kuchroo, V. K., & Kane, L. P.
- Affiliations
- University of Pittsburgh (US)
- Brigham and Women's Hospital (US)
- Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-10-01
- Volume
- 31
- Issue
- 19
- Pages
- 3963-3974
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3187355
- OpenAlex
- W2107777135
- Cited by
- 285
- References
- 39
- Citations by year
- 2026: 11 · 2025: 26 · 2024: 28 · 2023: 18 · 2022: 24 · 2021: 32 · 2020: 26 · 2019: 21 · 2018: 23 · 2017: 19 · 2016: 14 · 2015: 11 · 2014: 13 · 2013: 6 · 2012: 13
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM077629, GM077629)
- National Institute of Allergy and Infectious Diseases (R56AI067544, P01AI073748, AI067544, AI073748, R01AI067544)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- TIM-3, T cell receptor signaling, phosphotyrosine, immune exhaustion, T cell activation, Fyn, PI3K p85, chronic viral infection, agonistic antibodies
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Amino Acid Sequence, Animals, Humans, Lymphocyte Activation, Membrane Proteins, Molecular Sequence Data, Phosphoproteins, Receptors, Antigen, T-Cell, T-Lymphocytes, Signal Transduction, NF-kappa B, Transcription Factor AP-1, Phosphotyrosine, src-Family Kinases, Jurkat Cells, Adaptor Proteins, Signal Transducing, NFATC Transcription Factors, Proto-Oncogene Proteins c-fyn, Mice, ZAP-70 Protein-Tyrosine Kinase, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
